NVDA+0.84%AAPL−2.51%GOOGL−1.17%MSFT−2.04%AMZN−0.15%TSM+2.85%SPCX−1.20%AVGO+0.21%
StockVS

NASDAQ · Biotechnology · USD

Karyopharm Therapeutics Inc. (KPTI) Stock Analysis

Karyopharm Therapeutics Inc. (KPTI) is a Biotechnology stock listed on NASDAQ and quoted in US Dollar.

KPTI

$1.79

+$0.02 (+1.13%)

Sep 4, 2026 · Market close

Compare

Price History

Hover for the daily close. The dotted line marks the period open.

Compare KPTI with… →

KPTI Key Statistics

As of Sep 4, 2026
Trading
Open
$1.77
Previous Close
$1.77
Day's Range
1.76–1.84
52-Week Range
1.72–10.99
Volume
577.30K
BetaHow much the share price moves relative to the wider market. 1.0 moves in line with it; above 1.0 swings more, below 1.0 less.
0.95
Valuation
Market Cap
$40.60M
P/E Ratio
unprofitable
P/S ratioMarket value divided by annual revenue. Useful for companies that are not yet profitable, where a P/E cannot be calculated.
0.28
EPS (ttm)Profit attributable to each share over the last twelve months.
−14.45
Financials (FY)
Revenue (FY)
$146.07M+0.57%
Net Income (FY)
−$196.04M
Profit marginThe share of revenue left as profit after all costs and taxes.
−153.28%
Shares OutstandingThe total number of shares held by all investors. Market value is this figure multiplied by the share price.
22.68M
1-Year Return
−73.42%
Dividend and dates
Earnings Date
November 3, 2026
Avg Volume
1.36M

Only metrics the company reports are shown. Data provided by Yahoo Finance via yfinance. Updated daily.

KPTI Stock Return by Calendar Year

Calendar-year returns computed from daily closing prices. Partial years are shown muted and marked with an asterisk.

YearReturn
2026 (partial year)−75.68%
2025−27.42%
2024−21.85%
2023−74.56%
2022−47.12%
2021−58.46%
2020−19.25%
2019+104.59%
2018−2.40%
2017+2.13%
2016 (partial year)+38.44%

As of September 4, 2026.

KPTI Revenue and Earnings by Fiscal Year

FY ends December
Fiscal yearRevenueNet incomeNet margin
2025$146.07M−$196.04M−134.2%
2024$145.24M−$76.42M−52.6%
2023$146.03M−$143.10M−98.0%
2022$157.07M−$165.29M−105.2%
Fiscal yearRevenueGross profitOperating incomeNet incomeNet margin
2025$146.07M$140.12M−$90.71M−$196.04M−134.2%
2024$145.24M$139.23M−$119.44M−$76.42M−52.6%
2023$146.03M$141.09M−$129.54M−$143.10M−98.0%
2022$157.07M$151.86M−$142.20M−$165.29M−105.2%

Annual figures as reported, in the company's reporting currency. As of December 31, 2025.

KPTI Valuation vs Biotechnology Median

Median of 656 stocks
MetricKPTIBiotechnology medianvs median
P/S ratio0.2815.260.0x the median
Profit margin−153.28%0.00%153.3 pts below

Medians across 656 Biotechnology stocks that report the metric. Medians, not averages, so one outlier cannot move them. As of September 4, 2026.

Recent News

All 10 articles ↓

News provided by third-party sources. Not financial advice.

Analysis

Data-derived

Company Overview

The market values Karyopharm Therapeutics Inc. (KPTI) at $40.60M. It is classified in the Biotechnology industry, within the Healthcare sector. Headcount on file is 228.

Over the past 52 weeks the price has ranged from $1.72 to $10.99. The most recent close on file for KPTI is $1.79, dated September 4, 2026. That is +$0.02 (+1.13%) against the previous close. The latest close sits 4.07% above that 52-week low.

Financial Health

Fiscal 2025 revenue came to $146.07M. That is +0.57% against the prior fiscal year, when revenue was $145.24M. The same year closed with a net loss of $196.04M. The reported profit margin is −153.28%. That is 153.3 percentage points below the Biotechnology median of 0%. Earnings per share on a trailing basis come to −14.45.

Across the 4 fiscal years on file, revenue moves from $157.07M in 2022 to $146.07M in 2025. Of those 4 years, 0 report positive net income.

Valuation Assessment

No trailing P/E applies: the last reported earnings figure is negative. Measured against sales, the shares trade at 0.28 times revenue. On price-to-sales that is 0 times the Biotechnology median of 15.26. The medians here are taken across 656 Biotechnology companies that report the metric.

Over the trailing twelve months the price has returned −73.42%. Across 10 years the annualized return works out at −36.16%. Beta against the wider market is reported at 0.96. Annualized volatility over the trailing 10 years is 89.05%.

Growth & Income

The record shows no dividend for KPTI.

The strongest complete calendar year on file is 2019 at +104.59%; the weakest is 2023 at −74.56%. Of the 9 complete calendar years on file, 2 finished higher. So far in 2026 the price is −75.68%.

Peer Comparison

Karyopharm Therapeutics Inc. (KPTI) operates in the Biotechnology industry. Here is how it compares to its closest peers by market capitalization:

Company Ticker Market Cap P/E Ratio
Karyopharm Therapeutics Inc. KPTI $40.60M —
Vertex Pharmaceuticals Incorporated VRTX $138.42B 32.5
Regeneron Pharmaceuticals, Inc. REGN $85.22B 20.5
argenx SE ARGX $64.25B 40.1

The Biotechnology industry average P/E ratio is 12.6x. Karyopharm Therapeutics Inc. has no P/E ratio because it is not currently profitable.

Every figure above is read from this page's own data on each nightly rebuild. Informational only, not financial advice. As of September 4, 2026.

Related Biotechnology Stocks

VRTX

Vertex Pharmaceuticals Incorporated

$138.42B

 REGN

Regeneron Pharmaceuticals, Inc.

$85.22B

 ARGX

argenx SE

$64.25B

 MRNA

Moderna, Inc.

$58.11B

 RVMD

Revolution Medicines, Inc.

$45.01B

 ONC

BeOne Medicines AG

$40.53B
View all Biotechnology stocks →

Popular Healthcare Stocks

LLY

Eli Lilly and Company

$1.02T

 JNJ

Johnson & Johnson

$663.28B

 ABBV

AbbVie Inc.

$453.19B

 MRK

Merck & Co., Inc.

$370.89B

 UNH

UnitedHealth Group Incorporated

$356.47B
View all Healthcare stocks →

About Karyopharm Therapeutics Inc.

Karyopharm Therapeutics Inc., a commercial-stage pharmaceutical company, discovers, develops, and commercializes drugs directed against nuclear export for the treatment of cancer and other diseases in the United States. The company discovers, develops, and commercializes novel and small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein exportin 1 (XPO1). Its lead compounds include XPOVIO in combination with bortezomib and dexamethasone for the treatment of adult patients with multiple myeloma; in combination with dexamethasone for the treatment of adult patients with relapsed or refractory multiple myeloma; and for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL). It also develops Selinexor for treating hematological and solid tumor malignancies, including multiple myeloma, endometrial cancer, myelofibrosis, and DLBCL; and ELTANEXOR for treating other myeloproliferative neoplasms and TP53 wild-type solid tumors. In addition, the company has license agreement with Menarini Group to develop and commercialize selinexor for human oncology indications; license agreement with Antengene Therapeutics Limited to develop and commercialize selinexor, eltanexor, and KPT-9274 for the treatment and/or prevention of human oncology indications, as well as verdinexor for the diagnosis, treatment, and/or prevention of human non-oncology indications; and distribution agreement for the commercialization of XPOVIO with FORUS Therapeutics Inc. Further, the company has a collaboration with Bristol Myers Squibb company to evaluate novel cereblon E3 ligase modulator agent mezigdomide in combination with Selinexor in patients with relapsed or refractory multiple myeloma. Karyopharm Therapeutics Inc. was incorporated in 2008 and is headquartered in Newton, Massachusetts.

Visit website →